Lineage Cell Therapeutics, Inc. (LCTX) Q3 2023 Earnings Call Transcript


Start Time: 16:30 January 1, 0000 5:12 PM ET

Lineage Cell Therapeutics, Inc. (NYSE:LCTX)

Q3 2023 Earnings Conference Call

November 09, 2023, 16:30 PM ET

Company Participants

Brian Culley – CEO

Jill Howe – CFO

Gary Hogge – SVP, Clinical and Medical Affairs

Ioana Hone – Head, IR

Conference Call Participants

Joseph Pantginis – H.C. Wainwright

Abigail Gray – Baird

Kristen Kluska – Cantor Fitzgerald

Operator

Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investors section of Lineage’s website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage and recordings, reproductions or transmissions of this call without the expressed written consent of Lineage are strictly prohibited. As a reminder, today’s call is being recorded.

I would now like to introduce your host for today’s call, Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead.

Ioana Hone

Thank you, Jordan. Good afternoon and thank you for joining us. A press release reporting our third quarter 2023 financial results was issued earlier today, November 9, 2023, and can be found on the Investors section of our website. Please note that today’s remarks and responses to your questions reflect management’s views as of today only and will contain forward-looking statements within the meaning of federal securities laws.

Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company’s actual results or performance may differ materially from the expectations indicated by such forward-looking statements.

For a discussion of certain factors that could cause the company’s results or performance to differ, we refer you to the forward-looking statements



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *